Display options
Cite
Small W, Refaat T, Strauss JB, et al. Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial. J Radiat Oncol. 2015;4(4):395-400doi: 10.1007/s13566-015-0228-1.
Small, W., Refaat, T., Strauss, J. B., Gopalakrishnan, M., Bethke, K. P., Mendelson, E. B., Wolfman, J. A., Jovanovic, B. D., & Kiel, K. (2015). Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial. Journal of radiation oncology, 4(4), 395-400. https://doi.org/10.1007/s13566-015-0228-1
Small, William, et al. "Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial." Journal of radiation oncology vol. 4,4 (2015): 395-400. doi: https://doi.org/10.1007/s13566-015-0228-1
Small W, Refaat T, Strauss JB, Gopalakrishnan M, Bethke KP, Mendelson EB, Wolfman JA, Jovanovic BD, Kiel K. Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial. J Radiat Oncol. 2015 Dec;4(4):395-400. doi: 10.1007/s13566-015-0228-1. Epub 2015 Nov 02. PMID: 26779307; PMCID: PMC4710168.
Copy Download .nbib Format: NLM
Share it on

J Radiat Oncol. 2015 Dec;4(4):395-400. doi: 10.1007/s13566-015-0228-1. Epub 2015 Nov 02.

Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial.

Journal of radiation oncology

William Small, Tamer Refaat, Jonathan B Strauss, Mahesh Gopalakrishnan, Kevin P Bethke, Ellen B Mendelson, Judith A Wolfman, Borko D Jovanovic, Krystyna Kiel

Affiliations

  1. Department of Radiation Oncology, Cardinal Bernardin Cancer Center, Stritch School of Medicine Loyola University Chicago, 2160 S 1st Ave, Maguire Center, Rm. 2932, Maywood, IL 60153, USA.
  2. Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA; Department of Clinical Oncology, Alexandria University, Alexandria, Egypt; Northwestern Medicine Developmental Therapeutics Institute (NMDTI), Chicago, IL, USA.
  3. Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA.
  4. Department of Clinical Surgery-Breast Surgery, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA.
  5. Department of Radiology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA.
  6. Department of Preventive Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA.
  7. Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA.

PMID: 26779307 PMCID: PMC4710168 DOI: 10.1007/s13566-015-0228-1

Abstract

OBJECTIVE: The purpose of this study was to report the treatment-induced adverse events and cosmetic and treatment outcomes of accelerated partial breast irradiation (APBI) delivered with the MammoSite radiation therapy system (RTS) in breast cancer patients undergoing breast-conserving therapy (BCT).

METHODS: This is a prospective clinical trial that was approved by the institutional review board. The study included female breast cancer patients undergoing breast-conserving therapy in the form of surgery and APBI delivered with the MammoSite RTS. Patients and tumor characteristics, treatment-induced acute adverse events based on the Common Toxicity Criteria for Adverse Events (CTCAE) version 2.0, chronic AEs according to Radiation Therapy Oncology Group (RTOG) scale, treatment outcomes (including local control, disease-free survival, and overall survival), and cosmetic outcomes are reported.

RESULTS: The study included 36 eligible patients treated consecutively in our institution between November 2003 and August 2009. The age range was 45-83 years. A total of 29 patients had invasive disease (median size 1.1 cm), while 7 patients had in situ disease only (median size 0.8 cm). The skin distance in most of the patients (91.7 %) was ≥1 cm; only three patients (8.3 %) had skin distance <1 cm. The median balloon diameter was 5 cm (range 4-6 cm). At a median follow-up of 42 months (range 4-65 months), local control, disease-free survival, and overall survival were 100 %. None of the patients experienced any grade 3 or 4 toxicities; 16.7 and 5.6 % of the patients had late grade 2 fibrosis and telangiectasia, respectively. At last follow-up, cosmetic outcome was rated as good or excellent in 94 % of the patients.

CONCLUSION: APBI delivered with the MammoSite RTS is a feasible, tolerable, and effective treatment modality. Multicenter, randomized, controlled clinical trials with a larger number of patients are required for verification.

Keywords: Accelerated partial breast irradiation; Brachytherapy; MammoSite

References

  1. Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):987-1001 - PubMed
  2. Lancet. 2005 Dec 17;366(9503):2087-106 - PubMed
  3. N Engl J Med. 1992 Apr 23;326(17):1097-101 - PubMed
  4. N Engl J Med. 2002 Oct 17;347(16):1233-41 - PubMed
  5. J Am Coll Surg. 2013 Sep;217(3):497-502 - PubMed
  6. N Engl J Med. 2002 Oct 17;347(16):1227-32 - PubMed
  7. J Natl Cancer Inst. 2000 Feb 2;92(3):269-71 - PubMed
  8. Radiother Oncol. 2009 May;91(2):157-65 - PubMed
  9. Am J Surg. 2009 Jul;198(1):83-91 - PubMed
  10. Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 - PubMed
  11. Radiother Oncol. 2009 Jan;90(1):1-13 - PubMed

Publication Types

Grant support